Trevi Therapeutics (TRVI) Assets (2018 - 2026)

Trevi Therapeutics' Assets history runs 9 years deep, the most recent figure standing at $179.6 million for Q1 2026.

• On a quarterly basis, Assets rose 67.85% year-over-year to $179.6 million in Q1 2026; TTM through Mar 2026 was $179.6 million, a 67.85% increase from a year earlier, with the FY2025 full-year figure at $193.4 million, up 74.43% from the prior year.
• Assets retreated to $179.6 million in Q1 2026 per TRVI's latest filing, from $193.4 million in the prior quarter.
• Across five years, Assets topped out at $208.3 million in Q2 2025 and bottomed at $30.4 million in Q1 2022.
• The 5-year median for Assets is $107.0 million (2025), against an average of $116.8 million.
• Across the five-year window, Assets soared 306.26% in 2022 and tumbled 32.4% in 2024, its largest moves.
• Year by year, Assets stood at $123.0 million in 2022, then declined by 27.32% to $89.4 million in 2023, then rose by 24.05% to $110.9 million in 2024, then surged by 74.43% to $193.4 million in 2025, then retreated by 7.15% to $179.6 million in 2026.
• Per Business Quant, the three latest TRVI Assets figures stand at $179.6 million (Q1 2026), $193.4 million (Q4 2025), and $199.4 million (Q3 2025).